All Oncology News

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Alexis LeVee, MD, discusses treatment challenges associated with TNBC and ongoing trials that may improve outcomes for patients with early-stage disease.

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.

Historic donation unites two renowned institutions under one new world-class center created to end childhood cancer

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

China’s NMPA approved bireociclib for 2 indications in adult patients with HR+/HER2– breast cancer.

Perioperative nivolumab plus chemotherapy was approved by the European Commission for use in resectable PD-L1–positive non–small cell lung cancer.

An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.

Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

The FDA approved frontline retifanlimab/chemotherapy for metastatic SCAC and retifanlimab monotherapy for metastatic SCAC with progression on chemotherapy.

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

Huntsman Cancer Institute pioneers a clinical trial using deceased donor stem cells, expanding transplant options for patients with aggressive blood cancers.

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic for telisotuzumab vedotin in non–small cell lung cancer.

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.

Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.